NEW YORK — Laxxon Medical Corp. announced it has successfully developed a novel modified-release oral formulation of enobosarm for Veru Inc., utilizing its proprietary SPID® (Screen Printing Innovation Drug) technology. The formulation is designed to enhance bioavailability and optimize drug release, potentially offering improved treatment options for patients with cardiometabolic and inflammatory diseases.
The new tablet meets target release criteria, including reduced maximum plasma concentration (Cmax), delayed time to maximum plasma concentration (Tmax), a distinct secondary peak, and similar absorption levels (AUC) to historical immediate-release capsule data.
“This milestone underscores the strength of our SPID®-Technology in enhancing bioavailability and optimizing drug release profiles,” said Helmut Kerschbaumer, CEO of Laxxon Medical. “We are excited to support Veru on their product development pathway.”
SPID® technology enables precise control of drug delivery, allowing for sequential release of active pharmaceutical ingredients, processing of peptides with permeation enhancers, nanoparticle integration, and multi-compartment tablet designs — all scalable from laboratory to mass production.
Veru chairman, president, and CEO Dr. Mitchell Steiner said the partnership with Laxxon was a strategic move. “The resulting modified-release oral formulation of enobosarm has multiple benefits when treating the intended patient population and represents a significant advance over conventional dosage forms as we move towards Phase 3 clinical trials and potential commercialization, pending regulatory approval,” he said.
Enobosarm, a late-stage therapeutic candidate, is being advanced for potential use in patients with certain cardiometabolic and inflammatory conditions.
